Skip to main content

Advertisement

Fig. 4 | BMC Cancer

Fig. 4

From: Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

Fig. 4

PD-L1 and HLA-class I expression in NBL before the vaccination. IHC was performed on consecutive sections of FFPE tumor samples before the vaccination. Representative IHC images of PD-L1 and HLA-class I markers for the three enrolled patients (Pt1, 2, 3) are reported. Arrows indicate PD-L1 and HLA-class I positive tumor cells. Scale bar = 200 μm; inserted panels scale bar = 50 μm

Back to article page